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Abstract
Background: The surgical insult induces an inflammatory response that activates P38 MAP kinases
and solid tumours can also release cytokines. Therfore inhibition of these pathways may reduce
tumour growth We set out to examine the effects of P38-MAPK inhibition on apoptosis,
proliferation, VEGF release and cell cycle effects in-vitro and on primary tumour growth in-vivo.
Methods: 4T-1 cells (2 × 105cells/well) were incubated, in 24 well plates with control, 25, 50 or
100 ng/ml of SB-202190 for 24 hours. Cells were subsequently asessed for apoptosis, proliferation,
VEGF release and cell cycle analysis. Balb-c mice each received 1 × 106 4T1 cells subcutaneously in
the flank and were then randomised to receive control or SB202190 (2.5 μM/kg) by intraperitoneal
injection daily. Tumour size was measured alternate days and at day 24 animals were sacrificed and
serum VEGF assessed.
Results: P38-MAPK inhibition in-vitro resulted in a significant reduction in proliferation (75.2 ±
8.4% vs. 100 ± 4.3%, p < 0.05) and G1 cell cycle phase(35.9 ± 1.1% vs. 32.5 ± 0.6%, p < 0.05) but no
significant changes in apoptosis or VEGF levels. In-vivo, P38-MAPK inhibition resulted in an increase
in primary tumour growth (155.6 ± 34.9 vs. 86.7 ± 18.2 mm3, p < 0.05). P38-MAPK inhibition also
lowered circulating VEGF levels but this difference was not significant (101.9 ± 27.1 ηg/ml
compared to 158.6 ± 27.1 ηg/ml)
Conclusion: These findings demonstrate that P38-MAPK inhibition in-vitro reduces proliferation
and G1 cell cycle phase as well as promoting primary tumour growth in-vivo. These effects would
appear to be independent of VEGF.
Background
P38 mitogen activated protein kinases (MAPK) are 38-
kDa intracellular signal transduction proteins comprising
four variants; p38 α,  β,  γ and δ. Together with c-Jun,
amino-terminal kinase and p42/44 MAPK, p38-MAPK
forms the MAPK family[1]. MAPK are activated by phos-
phorylation by MAPK kinases (MKK), as part of intracel-
lular signalling cascades at which diverse extracellular
stimuli converge to initiate cellular responses. An impor-
tant role of MAPK is its activation by a wide variety of
stimuli including cytokines, endotoxin, BLP and other
stresses, which can ultimately result in the activation of
NF-κB[2]. Similarly, as with NF-κB, p38-MAPK has been
implicated as a critical mediator of the release of proin-
flammatory cytokines and positively regulates the expres-
sion of a variety of genes involved in the acute phase
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response such as TNF-α, IL-6 and other inducible enzymes
involved in malignant transformation such as VEGF,
ERGF and AP-1[3,4]. Expression of proinflammatory
cytokines has been reported to promote tumour cell pro-
liferation, host angiogenesis, inflammation and catabo-
lism in animal models and in cancer patients. Elevated
levels of pro-inflammatory cytokines have been described
in cell line supernatants, tumour specimens and serum of
patients with cancer[5,6]. Activation of the MAPK path-
way has been shown in the malignant transformation of
in-vitro  cell lines and in in-vivo  models of colon can-
cer[7,8]. P38-MAPK activation has been demonstrated in
many human cancers but the findings have not been con-
sistent[9]. Some studies have failed to find MAPK activa-
tion whereas others have demonstrated NFκB, p38 and
JNK activation in colonic polyps[10]. Again as with colon
cancer there have been variable reports of p38-MAPK acti-
vation in gastric cancer[11]. However, in human non-
small cell lung cancer p38-MAPK appears to be constitu-
tively activated and as a result could have an important
role in the pathogenesis and progression of certain human
cancers[9].
As result p38-MAPK, as a critical mediator of cellular
responses, is a suitable candidate as a novel therapeutic
strategy for targeting the malignant potential of tumours.
Therefore, in the present study we set out to investigate the
role of p38-MAPK inhibition using specific p38-MAPK
inhibitor (SB-202190) on apoptosis, proliferation, cell
cycle and VEGF release in-vitro and on tumour growth in-
vivo.
Methods
Reagents
DMEM, PBS, fetal calf serum, penicillin, streptomycin sul-
phate, and L-glutamine were purchased from Life Tech-
nologies (Paisley, Scotland). Propidine iodine (PI),
DMSO, PMSF, Nonidet P-40, DTT, HEPES, MgCl2, KCL,
NaCl, sodium citrate, Tris, Triton X-100, and EDTA were
purchased from Sigma Aldrich (St. Louis, MO). SN50 and
RNase were purchased from Calbiochem (San Diego, CA)
and Roche (East Sussex, UK), respectively.
SB-202190, 1 mg of dry powder was diluted with 3.02 mls
of DMSO and maintained as a stock solution of 1 mM at
-20°C. 10 μl of this solution was diluted in 10 mls of cul-
ture media to obtain a 1 μM working solution and this
solution was further diluted with culture media just prior
to use to obtain the desired concentrations for the experi-
ment. A control solution was obtained by diluting 10 μl of
DMSO in 10 mls of culture media and then further dilut-
ing this solution in line with the other concentrations just
prior to use.
Apoptosis Analysis
A murine adenocarcinoma cell line, 4T1 cells (a generous
gift from Dr. Fred Miller, Duke University) were main-
tained as monolayer culture in DMEM supplemented
with 10% heat-inactivated foetal calf serum, penicillin
(100 units/ml), streptomycin sulphate (100 μg/ml), and
L-glutamine (2.0 mM) at 37°C in a humidified 5% CO2
atmosphere. Cells (5 × 105cells/well) were incubated, in 6
well plates (Falcon, Lincoln Park, NJ), with control (vehi-
cle-PBS), 25, 50 or 100 μg/ml of SB-202190 for 6 and 24
hours. After the incubation period had finished the sus-
pension of cells was collected in non-adherent FACS tubes
(Falcon), and immediately centrifuged at 4°C for 10 min-
utes at 1,500 rpm. The cell pellet were gently resuspended
in 0.5 ml of hypotonic fluorochrome solution (50 μg/ml
PI, 3.4 mM sodium citrate, 1 mM Tris, 0.1 mM EDTA,
0.1% Triton X-100) and incubated in the dark before they
were analysed on a FACscan flow cytometer (Becton Dick-
inson, Lincoln Park, NJ). The forward scatter and side scat-
ter of 4T1 cells were simultaneously measured. The PI
fluorescence of individual nuclei with an acquisition of
fluorescence channel 2 was plotted against forward scat-
ter, and the data was registered on a logarithmic scale. The
minimum number of 10,000 events was collected and
analysed using the CellQuest software (Becton Dickin-
son). Apoptotic 4T1 cell nuclei were distinguished by
their hypodiploid DNA content from the diploid DNA
content of normal 4T1 cell nuclei. 4T1 cell debris was
excluded from analysis by raising the forward scatter. All
measurements were performed under the same instru-
ment setting.
Proliferation Analysis
A murine adenocarcinoma cell line, 4T-1 (ATCC, USA)
was maintained in culture in full media at 37°C, 5% CO2
and 90% humidity. 4T-1 cells (2 × 105cells/well) were
incubated, in 24 well plates (Falcon, Lincoln Park, NJ),
with control (vehicle-PBS), 25, 50 or 100 ng/ml of SB-
202190 for 24 hours. Two hours prior to the end of the
incubation period cells were labelled with BrdU (5-
bromo-2'-deoxyuridine) a labelling agent provided with a
commercially available Cell Proliferation ELISA kit
(Roche, Germany). Once the incubation period was fin-
ished, the labelling solution was removed by decanting
and tapping and cells were further processed and prolifer-
ation assessed according to the manufacturers instruc-
tions. 200 μl of Fixadent was added to each well and
incubated for 30 minutes at room temperature. Flicking
and tapping removed the Fixadent solution and 100 μl of
the anti-BrdU-POD (peroxidase) working solution was
added to each well and incubated for ninety minutes at
room temperature. The antibody conjugate was again
removed by flicking and tapping. The wells were then
washed three times with 200 μl of well washing solution.
After washing 100 μl of substrate solution was added toWorld Journal of Surgical Oncology 2009, 7:89 http://www.wjso.com/content/7/1/89
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each well and incubated at room temperature for 5-30
minutes until colour development was sufficient for pho-
tometric detection. To stop further photometric develop-
ment 25 μl of 1 M Sulphuric acid was added to each well
and mixed thoroughly on a shaker for 1 minute. The opti-
cal density of each well was determined within 30 min-
utes, using a microplate reader set to 450 nm. Control
samples were expressed as 100% and treated samples
expressed as a relative percentage.
VEGF Analysis
4T-1 cells (2 × 105 cells/well) were incubated, in 24 well
plates (Falcon), with control (vehicle-PBS), 25, 50 or 100
μg/ml of SB-202190 for 6 and 24 hours. After incubation
the suspension of cells were collected and immediately
centrifuged at 4°C for 10 minutes at 1,500 rpm. The
supernatant was collected and immediately further centri-
fuged at 4°C for 8 minutes at 10,000 rpm. Supernatant
was collected and stored at -80°C for determination of
VEGF concentrations using commercially available ELISA
kits (R&D Systems, Minneapolis, MN) according to the
manufacturer's instructions.
Cell Cycle Analysis
4T1 cells (1 × 106 cells/well) were incubated, in 6 well
plates, with control (vehicle-PBS), 25, 50 or 100 μg/ml of
SB202190 for 24 hours. After the incubation period had
finished the suspension of cells were collected in non-
adherent FACS tubes and immediately incubated with 0.5
ml of cooled methanol for 30 minutes on ice. After incu-
bation the suspension of cells were centrifuged at 4°C for
5 minutes at 1,500 rpm. The supernatant was discarded
and the cell pellet reconstituted with 0.25 ml of 10% pro-
pidine iodine solution and 0.25 ml of RNase (200 U/ml).
The reconstituted cell suspension was incubated at room
temperature for a further 30 minutes in the dark and then
filtered through a 35 μm mesh. Cell cycle analysis was per-
formed on a FACscan flow cytometer (Becton Dickinson)
with a minimum of 10,000 events collected and analysed
using the CellQuest software (Becton Dickinson).
In vivo animal studies
All animal experiments were carried out in accordance
within the Animal Act and under license from the Depart-
ment of Health and Children, Republic of Ireland. In in-
vivo experiments were performed in a blinded fashion. Six
to eight week old, male Balb-c mice were supplied by the
Biological Services Unit, University College Cork and were
allowed free access to food and water in a properly regu-
lated environment throughout the course the experiment.
Two hours prior to a flank subcutaneous injection of 0.5
× 106 of 4T-1 cells suspended in 200 μl PBS, female Balb-
c mice (n = 10 per group) were randomised to receive 200
μl of control or 2.5 μM/kg of SB-202190 via an intraperi-
toneal injection. Tumour size was measured on alternate
days and treatment continued on a daily basis for the
duration of the experiment. Tumour volumes were calcu-
lated using the following formula, V = √(A2+B2) where A
and B are the longest and shortest diameters respectfully.
After 24 days animals were sacrificed and blood collected
for cytokine analysis. Blood was collected for cytokine
analysis by intracardiac puncture and immediately
allowed to stand at 4°C overnight, before centrifugation
for 20 minutes at 10,000 rpm. Serum was collected and
stored at -80°C for determination of VEGF concentrations
using commercially available ELISA kits (R&D Systems)
according to the manufacturers' instructions.
Statistical Analysis
Differences in apoptosis, proliferation, cell cycle and
cytokine data compared using one-way analysis of vari-
ance with Tukey post-hoc analysis. Inter group differences
from in-vivo data were compared using student's t-test.
Differences in tumour volumes were compared using a
paired t-test. All values were expressed as mean (+/- SEM).
P < 0.05 was considered to be statistically significant.
Results
In Vitro
4T-1 cells treated with SB-202190 did not demonstrate
significantly increased spontaneous apoptosis compared
with control at 24 and 48 hours (7.45 ± 2.4% vs. 7.45 ±
2.4%, p > 0.05) (Fig. 1(a)). However, there did appear to
be an increase in apoptosis at both 24 and 48 hours, more
marked at 48 hours, but this was only seen with higher
doses but was not significant. Cells treated with 100 ng/
ml of SB-202190 had significantly reduced proliferation
in a dose dependent manner compared to control cells
(75.2 ± 8.4% vs. 100 ± 4.3%, p < 0.05) (Fig. 1(b)). Treat-
ment with 25, 50 or 100 ng/ml of SB-202190 had no
effect on spontaneous VEGF release at either 6 hours or 24
hours of incubation (p > 0.05) (Fig. 2). Treatment with
and 100 ng/ml of SB-202190 led to a significantly greater
proportion of cells staying in the G1/G0 resting or pre-
replication stage of the cell cycle than compared to control
at 24 hours (35.9 ± 1.1% vs. 32.5 ± 0.6%, p < 0.05) (Fig.
1(d)). Treatment with SB-2022190 did not result in any
reduction in the number of cells in the S (DNA synthesis)
or G2 + M (pre-mitotic and mitotic) phase of the cell cycle
(p > 0.05) and a similar pattern was seen at 12 hours.
In Vivo
After 24 days of treatment, the tumour volumes of ani-
mals that were treated with SB-202190 were significantly
greater than those of control treated animals (155.6 ±
34.9 vs. 86.7 ± 18.2 mm3, p < 0.05) (Fig. 3). At the time of
sacrifice, although treatment with SB-202190 did result in
lower circulating levels of VEGF, this difference was not
significant (p > 0.05) (Fig. 2).World Journal of Surgical Oncology 2009, 7:89 http://www.wjso.com/content/7/1/89
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The effect of SB-202190 on 4T-1 cells (a) spontaneous apoptosis (Cells 5 × 105 were treated with control (vehicle), 25, 50 or  100 μg/ml of SB-202190 for 24 and 48 hours), (b) proliferation (Cells 2 × 105 were treated with control (vehicle), 25, 50 or 100  μg/ml of SB-202190 for 24 hours, * = p < 0.05), (c) cell cycle analysis (Cells 5 × 105 were treated with control (vehicle), 25, 50  or 100 μg/ml of SB202190 for 24 hours, * = p < 0.05) and (d) Spontaneous VEGF release (Cells 5 × 105 were treated with con- trol (vehicle), 25, 50 or 100 μg/ml of SB-202190 for 6 and 24 hours) Figure 1
The effect of SB-202190 on 4T-1 cells (a) spontaneous apoptosis (Cells 5 × 105 were treated with control (vehi-
cle), 25, 50 or 100 μg/ml of SB-202190 for 24 and 48 hours), (b) proliferation (Cells 2 × 105 were treated with 
control (vehicle), 25, 50 or 100 μg/ml of SB-202190 for 24 hours, * = p < 0.05), (c) cell cycle analysis (Cells 5 × 
105 were treated with control (vehicle), 25, 50 or 100 μg/ml of SB202190 for 24 hours, * = p < 0.05) and (d) 
Spontaneous VEGF release (Cells 5 × 105 were treated with control (vehicle), 25, 50 or 100 μg/ml of SB-202190 
for 6 and 24 hours).
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Serum VEGF levels for control and SB-202190 treated ani- mals Figure 2
Serum VEGF levels for control and SB-202190 
treated animals. Animals (n = 10, per group) were ran-
domised to receive control (vehicle) or SB-202190 (2.5 μM/
kg) via an intraperitoneal route on a daily basis. After 24 days 
animals were sacrificed and blood was collected by intracar-
diac puncture, left to stand overnight prior to centrifugation 
for 20 minutes at 10,000 rpm. Serum was collected and 
stored at -80°C for determination of VEGF concentrations 
using commercially available ELISA kits according to the man-
ufacturer's instructions.
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Tumour volumes over time in response to treatment with  control and SB-202190 treated animals Figure 3
Tumour volumes over time in response to treatment 
with control and SB-202190 treated animals. Animals 
(n = 10, per group) were randomised to receive control 
(vehicle) or SB-202190 (2.5 μM/kg) via an intraperitoneal 
route on a daily basis. (* = p < 0.05).
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Discussion
P38-MAPK inhibition has been shown to have a survival
benefit in a number of in-vivo models of sepsis[12]. This
survival benefit has been shown to be dependent on a sig-
nificant reduction in the levels of circulating proinflam-
matory cytokines as a consequence of down regulation of
p38 MAPK in-vivo. Many tumour cell lines, tumour speci-
mens and serum of patients with cancer have been shown
to have elevated levels of proinflammatroy
cytokines[13,14]. Proinflammatory cytokines have also
been reported to promote cell proliferation and have been
associated with increased potential for tumour
growth[15]. Given that human non-small cell lung carci-
noma demonstrates selective activation of p38-MAPK, it
would provide a mechanism of targeting malignant cell
growth or transformation. In-vitro p38-MAPK inhibition
did show some potential as a possible strategy with a
trend of increasing apoptosis and reduced proliferation. It
also had some reduction in VEGF release and beneficial
effects on cell cycle kinetics. However, in-vivo p38-MAPK
inhibition led in a significant increase in primary tumour
growth, which was independent of VEGF. We have dem-
onstrated similar effects with NFκB inhibition; increased
primary tumour growth independent of VEGF with down
regulation of NFκB in tumour extract (unpublished data).
Although the effect of p38-MAPK inhibition in animal
models of sepsis and human endotoxaemia has been
shown to be beneficial, our results show that any anti-
tumourgenic trends seen in-vitro do not translate to a ben-
eficial effect in-vivo. The role of p38 MAPK in human can-
cers is unclear and confusing[10,16]. Some reports have
shown p38-MAPK activation in human cancers whereas
others have not demonstrated such activation. In other
studies the pattern of p38-MAPK activation has been
inconsistent and equivocal. Our study showed that
although p38-MAPK inhibition appeared to have benefi-
cial effects in terms of malignant potential on a cell line in
vitro, this effect was not translated to the same cell line in-
vivo. This may well be due to a dampening of the inflam-
matory response and the necessary host inflammation to
recognise the tumour as non self, but may also relate to
the wide variety of genes P38-MAPK can activate.
Although, P38-MAPK may be a critical mediator of the
inflammatory response its role in tumour growth is rela-
tively unknown. Indeed many studies suggest that the role
of p38-MAPK cascade in human cancers may be cell or tis-
sue specific which would make its effect unpredictable
and indeed this effect may vary between the same tumour
types[17]. This effect in the current study does not appear
to be mediated via VEGF but it may be difficult to identify
a particular mediator. This may be due to the variation of
P38-MAPK activation in human tumours and the diverse
range of intracellular mediators mediated via p38 MAPK.
P38-MAPK inhibition can have some effects in-vitro but
this effect has not translated into benefit in an in-vivo set-
ting. Although in-vivo this effect does not appear to be
mediated via VEGF, further studies are needed to identify
the pathways involved following p38-MAPK activation or
inhibition.
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